The con¯uence of two distinct but related activities in the past 10 years has dramatically accelerated eorts towards the discovery and development of novel drugs to treat cancer. The ®rst is a rapidly emerging understanding that a number of distinct tyrosine kinases play roles in diverse but fundamentally important aspects of tumor progression (growth, survival, metastasis and angiogenesis). The second is the discovery that small molecule compounds have the capacity to potently and selectively inhibit the biochemical function of tyrosine kinases by competing for ATP binding at the enzyme catalytic site. These observations have been conjoined in major eorts to bring forward into clinical development novel cancer drugs with the potential to provide both clinical ecacy and improved tolerability. The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical tumors (receptor and/or ligandcompetitive antibodies, intrabodies, antisense ribonucleotides, ribozymes, phosphatase inhibitors or SH2/SH3-directed agents). Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are to be developed into clinically useful cancer chemotherapeutic agents. Oncogene (2000) 19, 6574 ± 6583.
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Origin of species ± brief overview of substrate-based inhibitors of protein tyrosine kinases Among all non-traditional (non-DNA-directed) cancer targets for which pharmacological intervention is feasible, there are none that have generated as much widespread interest, and have invoked as much resource investment in both the public and private sectors in the past 7 years, as have the tyrosine kinases. Several excellent recent reviews have described the functions of various tyrosine kinases in the key pathways that drive tumor progression, from ®rst genetic insult to disseminated disease (Hanahan and Weinberg, 2000; Hunter, 2000; Gibbs, 2000) . Key among these are the receptor tyrosine kinases which initiate signal transduction in tumor cells or endothelial cells following the binding of the growth factors EGF, PDGF and VEGF. There are also several excellent reviews that provide detailed overviews of the work accomplished to date to understand the molecular pharmacology of small molecule inhibitors of receptor tyrosine kinases (Sedlacek, 2000; Levitzki, 1999; Lawrence and Niu, 1998) . Without summarizing each of these important reviews, they provide an appropriate context for understanding the obstacles and triumphs that have led, very recently, to the ®rst reproducible, objective clinical responses in cancer patients treated with tyrosine kinase inhibitors.
The catalytic function of protein tyrosine kinases involves the simple transfer of the gamma phosphate of ATP to hydroxyl group of a tyrosine residue of proteins (or peptides) encompassing a diversity of primary sequences and tertiary structures (Songyang and Cantley, 1998) . Each of the substrates in the phosphotransfer reaction, the tyrosine hydroxy group and ATP, represent reasonable pharmacological starting points for the design of substrate analogs and competitive inhibitors of tyrosine kinases. A diverse set of pharmacophores, including natural products (lavendustins and erbstatins) and synthetic tyrosine mimetics, have all been characterized on the basis of their ability to competitively inhibit tyrosine kinase function (Levitzki, 1999) . These compounds tended to have poor potency (particularly in cells), to yield relativelȳ at structure-activity relationships, and to be somewhat non-speci®c in their kinase inhibition . Attacking this reaction from the other side, by identifying compounds that mimic ATP, was originally thought to be even less tractable. As reviewed by Lawrence and Niu (1998) , the theoretical obstacles were immense. First, the primary sequence of the ATPbinding pocket of all kinases is highly conserved, and therefore selectivity, if not speci®city, represents a signi®cant technical challenge. Secondly, the intracellular concentration of ATP can exceed 5 mM, particularly in tumor cells, while the K m for ATP in most kinase active sites is in the micromolar range, thus ensuring full-time saturation by ATP. ATPcompetitive inhibitors would need to exhibit at least nanomolar inhibitory kinetic constants to eectively compete in this circumstance (Lawrence and Niu, 1998) . Finally, there are multiple non-kinase ATPdependent enzymes important to normal physiology, and so an indiscriminant ATP mimetic would likely have toxicities that were pharmacologically and medically unacceptable.
This theoretical logjam was broken in convincing fashion when the tyrosine kinase inhibitory activities of anilinoquinazolines were ®rst described in 1994 by three separate groups (Fry et al., 1994; Ward et al., 1994; Osherov and Levitzki, 1994) . For example, the work of Fry et al. (1994) at Warner Lambert revealed that 4-anilinoquinazolines were potent (nM) inhibitors Oncogene (2000) 19, 6574 ± 6583 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: MJ Morin of the EGFR tyrosine kinase with good cell activity and profound biochemical selectivity relative to other kinases within the tyrosine kinase family. Further elaboration of structure-activity relationships rich in new possibilities resulted in ATP-competitive inhibitors of the EGFR tyrosine kinase with K i values in the single digit picomolar range. It is interesting to note that the Michaelis-Menten equation could not be used to derive the K i values of these molecules. So avid was the binding of compound to the ATP site, the conventional approximation that total and free enzyme concentrations were equivalent did not apply under these conditions. These accomplishments, which may be among the most important in pharmacology for the last 10 years, were largely achieved by empirical screening and iterative medicinal chemistry. Even more new chemotypes may emerge as structure-based design becomes more commonly applied to the identi®cation of both active site-and allosteric site-directed inhibitors for an ever-widening slate of tyrosine kinase targets. While these early lead molecules had biopharmaceutical properties which were by-and-large incompatible with oral bioavailability and good duration of exposure in vivo, the results spurred on a number of groups, which have since identi®ed and developed tyrosine kinase inhibitors with signi®cant potential to treat clinical cancer.
Selected development candidates ± updates
PDGFR inhibitors: STI 571 and SU101 STI 571 (CGP57148B) Among all of the candidates currently in clinical development, perhaps none has provided as much`proof of concept' for the clinical ecacy and tolerability of small molecule tyrosine kinase inhibitors as has STI 571. Originally disclosed by Novartis as a multitrophic tyrosine kinase inhibitor, STI 571 was described by Druker et al. (1996); and Druker and Lydon (2000) as having potent activity vs the translocation product bcr-abl, the transforming tyrosine kinase found in virtually all CML cells expressing the Philadelphia chromosome (Kurzrock et al., 1988; Kelliher et al., 1990) . The inhibition of v-abl, bcr-abl and PDGFR autophosphorylation by the 2-phenylaminopyrimidine STI 571 (Figure 1 ) at nanomolar concentrations was found to translate to both in vivo anti-tumor activity, and to the inhibition of clonogenicity of blasts from CML patients (le Coutre et al., 1999; Druker et al., 1996) . The results of a clinical trial in which STI 571 was administered to CML and ALL patients expressing bcr-abl in their leukemic blasts were most recently summarized in May 2000 (Talpaz et al., 2000) . STI 571 was used to treat 33 acute leukemia patients, which included 21 myeloid blast crisis CML patients and 12 bcr-abl-positive ALL or lymphoid blast crisis CML patients. Clinical responses, as de®ned by a decrease in the percentage of patients achieving reduction in bone marrow blasts to 15% of pre-treatment levels, were observed in 55% of myeloid blast crisis patients, with complete responses in 22% of these patients. The response rates in patients with bcr-abl positive ALL and lymphoid blast crisis of CML were higher (82% with 55% complete responses), but all of the patients with lymphoid leukemias relapsed on drug between 45 and 81 days. Of 19 responding patients, 10 experienced Grade 3 ± 4 neutropenia. This response rate, and the incidence of Grade 3 ± 4 toxicity, compares very favorably to the standard of care cytotoxic chemotherapies for CML. As such, more de®nitive trials assessing the ecacy and safety of STI 571 are ongoing in CML.
It is interesting to speculate as to the biochemical basis for both the ecacy and the toleration pro®le of STI 571. Two other tyrosine kinases potently inhibited by STI 571, c-kit and PDGFR, are both believed to play important roles in maintaining bone marrow stroma ± progenitor cell interactions (Ashman, 1999; Sungaran et al., 2000) . Thus, inhibition of c-kit and PDGFR could also account for some of the compelling clinical activity of STI 571 in CML, as well as for its toxicity pro®le (neutropenia). Treatment of a c-kit expressing a human myeloid leukemia cell line, M-07e, with STI 571 before stimulation with kit ligand inhibited c-kit autophosphorylation, activation of mitogen-activated protein (MAP) kinase, and activation of Akt, with an IC 50 of 100 nM (Heinrich et al., 2000) . STI 571 was even more potent in a human mast cell leukemia cell line (HMC-1) expressing an activated mutant form of c-kit. Similar results have also recently been reported in nonhematopoietic tumor cells . The ecacy and safety hypotheses for inhibition of c-abl in CML may perhaps only be addressed with a more selective abl tyrosine kinase inhibitor. Given the apparent therapeutic bene®t of STI 571, this may be largely an academic question, but one with important implications as one tries to rationalize the desired selectivity pro®les of tyrosine kinase inhibitors most likely to generate both ecacy and safety in humans.
SU101 (le¯unomide; HWA 486) Le¯unomide was originally described and developed as an inhibitor of dihydroorotate dehydrogenase, a key enzyme in the de novo synthesis of pyrimidines, for use as an immunosuppressive or anti-arthritic agent (Bartlett and Schleyerbach, 1985; Kuo et al., 1996) . Le¯unomide has shown signi®cant activity as a treatment for rheumatoid arthritis (Smolen and Emery, 2000; Cohen et al., 2000b) , and was launched by Aventis as Arava 2 in the US and elsewhere beginning in 1998. Extending the work of others (Mattar et al., 1993; Xu et al., 1995) , Shawver and co-workers reported that micromolar concentrations of le¯unomide inhibited the autophosphorylation of the tyrosine kinase receptors for PDGF and VEGF (Shawver et al., 1997) . The compound was also eective at blocking mitogenesis stimulated by both PDGF and EGF, but exogenous uridine could not reverse the eect of le¯unomide on PDGF mitogenesis, suggesting that inhibition of the receptor tyrosine kinase, and not inhibition of pyrimidine pools, was a key pharmacological activity. The inhibition of EGF-induced mitogenesis by le¯u-nomide was reversed in part by uridine (Shawver et al., 1997) , despite the fact that le¯unomide and close-in analogs also have inhibitory activity vs the EGFR tyrosine kinase (Ghosh et al., 1999) .
Le¯unomide/SU101 is clearly a tyrosine kinase inhibitor with multiple biochemical eects, and readily generates a predominant active metabolite (SU0020 or A771726; Figure 1 ) that has a complex inhibitory pro®le of its own (Hamilton et al., 1999) . SU 101 was, nonetheless, progressed into clinical trials by SUGEN (now part of Pharmacia). A Phase I study in cancer patients revealed that SU 101 was well-tolerated as a 24 h continuous i.v. infusion at doses up to 443 mg/m 2 / wk. At this dose, the plasma concentration of the active metabolite was maintained at levels sucient to block both PDGFR and EGFR signaling, as well as pyrimidine biosynthesis . Toxicities were relatively minor (Grade 1 ± 2 nausea, vomiting and fever in approximately 20% of all courses given). Surprisingly, hematopoietic toxicities and hemolysis, which had been noted in the preclinical experience with SU 101, were not seen in this Phase I population. One partial response was seen in 26 patients receiving an average of two courses each; the responding patient received 13 courses (52 infusions) to treat an anaplastic astrocytoma, and had a notable (450%) reduction in one measurable lesion . SU 101 has been reported to be in advanced trials for multiple solid tumor types, but recent disclosures (Garber, 2000) indicate that Phase III trials in at least one tumor type (glioblastoma) have been abandoned. The status of other trials (ongoing Phase II trials for ovarian and NSCLC; planned Phase III trials for prostate, colon and NSCLC) is uncertain at the present time. have been equally compelling. The pharmacological characteristics of Iressa 2 were ®rst described in 1996 (Wakeling et al., 1996; Woodburn et al., 1997) as a potent and selective inhibitor of the EGFR tyrosine kinase. This quinazoline-based compound ( Figure 1 ) is an ATP-competitive inhibitor of the EGFR tyrosine kinase (IC 50 25 nM) with 50-fold selectivity relative to closely homologous erbB family members (IC 50 for erbB2 1 ± 3 mM) and even greater selectivity for more divergent tyrosine kinases. It demonstrates good cellular potency (80 nM IC 50 for inhibition of EGFdependent mitogenesis) and robust, dose-dependent anti-tumor ecacy in a variety of human tumor xenografts (Woodburn et al., 1997) . These results have been most recently extended to show that Iressa 2 has in vivo ecacy in a diverse human tumor xenograft models both with (Ciardello et al., 2000) and without (Sirotnak et al., 2000) highly activated EGFR signaling pathways. Of equal interest are the observations that Iressa 2 combines with standard cytotoxic agents (platinums, taxanes, topoisomerase I inhibitors, etc.) to produce additive or supra-additive anti-tumor ecacy in vivo without exacerbation of the toxicity of the co-administered cytotoxics. The ®ndings that tumor EGFR density does not predict ecacy when the compound is used in conjunction with cytotoxic agents have signi®cantly impacted the development strategy employed by AstraZeneca as Iressa 2 moves towards pivotal clinical trials.
Multiple Phase I trials with Iressa 2 have been summarized, and the results revealed reasonable pharmacokinetics, good toleration and the ®rst signs of clinical ecacy when used as a single agent in patients with advanced disease Baselga et al., 2000; Kelly et al., 2000) . Following oral administration of a single dose (50 mg), maximum plasma drug concentrations (mean 45 ng/ml) occurred 1 ± 5 h post-dose. The mean terminal t 1/2 was 34 h. Inter-subject variability in exposure was signi®cant following single and multiple administration (up to sevenfold at each dose level), but exposure increased proportionally with dose, with no apparent change in terminal t 1/2 across the dose range tested (Kelly et al., 2000) . In a larger dose-escalation trial, Ferry and collaborators administered Iressa 2 at doses of 50 ± 700 mg once daily, given orally for 14 days followed by 14 days of observation . In total, 64 patients with advanced disease, who had each progressed while on prior chemotherapy, completed 145 cycles. C max and AUC 0-24h were proportional across the entire dose range (mean values 113 ± 2255 ng/ml and 1.8 ± 38.5 mg.h/ml, respectively). As in single dose studies, Iressa 2 showed a long terminal elimination half-life (mean of 46 h). Iressa 2 was very well-tolerated in this study; the most common adverse events were diarrhea and acne-like skin rash (Grade 1 ± 2). Acne-like skin rashes have emerged as a common, mechanism-based adverse event for EGFR inhibitors, but the speci®c toxicological eect in the skin is not yet well understood. Grade 3 ± 4 adverse events were shown to be rare with Iressa 2 treatment, and were generally ascribed to disease progression. The doselimiting toxicity, de®ned at the 700 mg dose level, was Grade 3 diarrhea .
A compelling level of ecacy was also revealed in these early trials . Anti-tumor responses were most evident among the 16 NSCLC patients treated with Iressa 2 ± two had an objective partial response, two patients had signi®cant regression of disease and two patients had stable disease. Similar pharmacokinetic and safety pro®les were noted in a separate study (Baselga et al., 2000) , one that also revealed the potential for ecacy from Iressa 2 in patients with advanced prostatic and head-neck cancers. These early results added importantly to the proof-of-concept that selective tyrosine kinase inhibitors could have signi®cant single agent ecacy, as measured by objective tumor regressions, in patients with advanced disease. The clinical observations have therefore recapitulated the pre-clinical data showing that Iressa 2 increased apoptosis and regressions in human tumor xenograft models (Ciardello et al., 2000) .
The Iressa 2 data indicate that the ecacy of these agents can be measured using more classically de®ned clinical endpoints. There will undoubtedly be signi®-cant value in the use of pharmacodynamic and surrogate endpoints to guide dose-intensi®cation or to pre-select patients for whom other tyrosine kinase inhibitors might represent the most promising treatment option. Pharmacodynamic endpoints have not played a major role in the early development of EGFR tyrosine kinase inhibitors, despite the fact that several reasonable options exist, including both invasive techniques (direct measurement of tumor-derived or normal tissue-derived EGFR phosphotyrosine, phosphorylation of down-stream signaling molecules; apoptosis markers) and non-invasive techniques such as PET imaging of metabolically modulated tumors (Pollack et al., 1999; Goss et al., 2000; Allen et al., 2000) . Given the overall safety and toleration pro®le of Iressa 2 , AstraZeneca has committed to an aggressive development strategy, which includes two large Phase III studies to assess the use of Iressa 2 in combination with cis-or carbo-platinum plus a taxane or gemcitabine in ®rst-line therapy for NSCLC (trials 14 and 17), as well as a Phase II trial (trial 16) to con®rm the single agent activity of Iressa 2 in patients with advanced NSCLC (Kelly et al., 2000) . It is important to note that these trials do not call for a prospective selection for patients with tumors with some prede®ned level of EGFR over-expression. All epithelial tumors express some EGFR, and in the disease target here, NSCLC, tumors often present with a high proportion of EGFR over-expression (up to 80 ± 90% in advanced disease). The strategy is also consistent with pre-clinical data suggesting that ecacy in drug combinations may not be determined in large part by the level of EGFR over-expression in tumors (Sirotnak et al., 2000) . Results are expected from these pivotal trials in a late-2001 or early-2002 timeframe.
OSI-774 (CP-358,774) CP-358,774 is also a potent and selective quinazoline-based inhibitor of the EGFR function (Figure 1 ). This compound is a reversible, ATP-competitive inhibitor (IC 50 of 2 nM) of the EGFR tyrosine kinase, with greater than 500-fold selectivity against other tyrosine kinases, such as the closely related erbB2 kinase, as well as v-src, c-abl and the insulin and IGF-1 receptors, . CP-358,774 inhibits the autophosphorylation of the EGF receptor in a variety of EGFR over-expressing tumor cells (IC 50 =20 nM), and produces cell cycle arrest and apoptosis in multiple cell types Barbacci et al., 1997; Iwata et al., 1997) . In vivo, CP-358,774 eectively inhibits EGFR-speci®c tyrosine phosphorylation in human tumor xenografts (ED 50 of 10 mg/kg p.o. when given as a single dose) with signi®cant duration of action; daily dosing produces substantial growth inhibition and regressions in human tumor xenografts (Pollack et al., 1999) . Moreover, the dose-response for tumor growth inhibition shows good agreement with the dose-response for inhibition of EGFR-phosphotyrosine in tumors from treated animals. As with Iressa 2 , CP-358,774 was found to generate additive anti-tumor activity when used in combination with cis-platinum and other cytotoxic agents, without exacerbating the toxicities of the other chemotherapeutants (Pollack et al., 1999) .
Clinical studies with CP-358,774 have revealed that the agent is well-tolerated at oral doses that achieve plasma concentrations projected to be required for anti-tumor ecacy in humans (400 ± 500 ng/ml). In one study, escalating doses were administered orally once every week . Eighteen patients with advanced solid tumors were treated at ®ve doses (100 ± 1000 mg) for a maximum period of 24 weeks. Toxicities were observed only at doses higher than 200 mg/week, and included mild fatigue, Grade 2 maculopapular (acneiform) rash, Grade 2 nausea, and Grade 2 diarrhea. Like Iressa 2 , CP-358,774 exhibited intra-and inter-subject variability in exposure, but dose-proportional increases in exposure were observed throughout the 100 ± 1000 mg weekly dose range. During the ®rst 24 h following a single dose, the C avg Oncogene Tyrosine kinase inhibitors in cancer treatment trials MJ Morin (0.9 ± 4.8 mg/ml for 100 ± 1000 mg doses, respectively) was some two-to 10-fold above the projected ecacious plasma concentration. No maximally tolerated dose or dose-limiting toxicity was discerned in this study. In a second Phase I study (Siu et al., 1999) , patients were given CP-358,774 tablets in a variety of dose schedules, culminating in daily dosing at the maximally tolerated dose. The target C avg of 400 ± 500 ng/ml was achievable at doses at and above 100 mg/day on a well-tolerated schedule (C avg values following continuous daily dosing at the 50, 100 and 200 mg/day levels were 432, 973 and 2120 ng/ml, respectively). Dose-limiting diarrhea was encountered at the 200 mg/day level. An intermediate dose of 150 mg/day was subsequently de®ned as the maximally tolerated dose (two of three patients had Grade 1 diarrhea with loperamide support).
Siu and co-workers also made eorts to understand the`characteristic' Grade 1 ± 2 acneiform rash seen in patients treated with CP-358,774, which was limited to regions of the upper body where adolescent acne is usually manifest (face, back and scalp). Histopathology of skin biopsies showed subepidermal neutrophilic in®ltration and epidermal hyperproliferation (Siu et al., 1999) . While the precise cytopathic basis for the acneiform rash has not yet been determined, the consistent clinical observations with three dierent agents targeting EGFR function (CP-358,774, Iressa 2 and Imclone's C-225 antibody) suggest that this is a mechanism-based ®nding (Siu et al., 1999; Cohen et al., 2000b) . Skin changes are consistently noted in preclinical studies with rodents exposed to CP-358,774 for extended dosing periods, and these toxicological results are analogous to the skin changes seen in the waved-2 mouse, which has a mutated and marginally functional EGFR tyrosine kinase (Luetteke et al., 1994) .
Early ecacy readouts from ongoing Phase II clinical trials with CP-358,774 have been compelling. The agent appears to have a broad potential to treat a variety of human solid tumors, including NSCLC, breast, ovarian and squamous head and neck tumors (Bonomi et al., 2000; Allen et al., 2000; Siu et al., 2000; Hammond et al., 2000) . For example, in 34 NSCLC patients who had failed prior chemotherapy, daily oral doses of 150 mg CP-358,774 were well-tolerated, with a maculopapular (acneiform) rash being the most common adverse event reported. In 56 total patients evaluable for tumor response, there have been six partial responses in the lung and/or liver at 8 weeks and several patients with stable disease (Bonomi et al., 2000) . In 71 patients with refractory squamous carcinomas of the head and neck, CP-358,774 was again found to cause a reversible acneiform rash and Grade 1 ± 2 diarrhea. Of 78 patients evaluable for response, there have been at least eight con®rmed partial responses and 23 patients with stable disease (Siu et al., 2000) . These preliminary results indicate that CP-358,774 is generally well-tolerated and demonstrates evidence of single agent anti-tumor activity in patients with recurrent head and neck cancer, as well as in treatment-refractory NSCLC.
Due to signi®cant interests in both CP-358,774 and CI-1033, P®zer was directed to divest one of these two agents as a condition of their acquisition of Warner Lambert in 2000. As such, Oncogene Science (OSIP) has taken over complete responsibility for the development of CP-358,774, which is now formally referred to as OSI-774.
CI-1033 (PD183805) As described above, the selective and reversible inhibitors of the EGFR tyrosine kinase appear to oer the promise of therapeutic ecacy coupled to reasonable tolerability. It is important to note, however, that the therapeutic index of neither Iressa 2 nor CP-358,774 has yet to be fully elaborated, and that there may be signi®cant proximity between the maximally tolerated doses and the ecacious doses for both agents. Moreover, the ecacy of neither agent has yet to be established in a blinded, placebo controlled study. As such, there continues to be an opportunity to discover and develop distinctly dierent EGFR tyrosine kinase inhibitors with even greater potential for ecacy and a broader spectrum of activity. CI-1033 is one such distinctly dierent development candidate. As recently reviewed by David Fry of the former Warner Lambert organization, signaling through the erbB family of tyrosine kinase receptors often involves complex crosstalk among the members of that receptor family . The four family members (EGFR or erbB; erbB2, erbB3 and erbB4) are known to intensify their kinase-dependent transforming signals via the formation of heterodimers with each other (Tzahar et al., 1996) . There is, therefore, a compelling rationale to consider the potential utility of nonspeci®c but selective inhibitors that eectively block the function of the erbB family but do not inhibit more structurally diverse tyrosine kinases.
There is also a strong rationale to consider irreversible tyrosine kinase inhibitors. The reversible inhibitors have apparently generated clinical ecacy with dosing regimens designed to maintain plasma concentrations at fairly high levels for extended periods of time. The optimal dosing paradigm for an irreversible inhibitor would be less likely to require prolonged exposure. Moreover, the`absolute ®nality' of the irreversible inhibitors could conceivably provide signi®cant advantages in terms of antitumor ecacy. To be balanced, a multi-tropic and irreversible inhibitor would also have the potential to generate a toxicity pro®le that was dierent and, perhaps, without advantages relative to the more selective, reversible inhibitors. Preclinical data suggest that irreversible EGFR tyrosine kinase inhibitors can generate signi®cant ecacy with good toleration (Vincent et al., 1999) , but the ultimate utility of these agents can only be determined in clinical trials.
Homology modeling of ATP binding to the pocket of EGFR suggested that the thiol of cys773 would be a key potential site for attack by a rationally designed irreversible ATP-mimetic. One compound containing an acrylamide functionality at the six position of the 4-anilinoquinazoline nucleus (Figure 1 ) was found to have a profoundly rapid onset and long-lasting inhibition of both EGFR and erbB2 in tumor cells, and to be selective relative to non-erbB tyrosine kinases (Fry et al., 1998) . When compared to very closely related reversible analogs (in which the acrylamide double bond was reduced), the 6-substituted irreversible analogs were more potent in vitro and had signi®cantly greater ecacy in vivo. Further improve-ments (addition of substitutions which also improved water-solubility) led to the elaboration of PD 183805/ CI-1033 (Figure 1) . Like its predecessors, this compound has excellent (low nM) potency against erbB2 and EGFR in both enzyme-and cell-based assays (Sherwood et al., 1999) . Consistent with a predicted advantage relative to reversible inhibitors, CI-1033 potently inhibits human tumor xenografts when dosed as infrequently as once per week, and a single dose eliminated the level of EGFR phosphorylation in tumors for longer than 72 h (Vincent et al., 1999) . Like CP-358,774, CI-1033 combines well in drug combinations with cytotoxic agents. Given 24 h after gemcitabine, CI-1033 produced a signi®cant increase in the apoptotic fraction in tumors over treatment with either drug alone . CI-1033 also eectively decreased the clonogenicity of human tumor cells taken from patients , with notable responses seen in breast (67%), NSCLC (60%) and ovarian cancer specimens. CI-1033 Phase I clinical trials have recently been initiated, but data on pharmacokinetics or safety have not yet been disclosed.
Small molecule tyrosine kinase inhibitors targeting angiogenesis pathways
There are multiple tyrosine kinase receptors which appear to have key roles in the generation of new tumor blood vessels and, as such, represent reasonable targets for cancer chemotherapy (for excellent recent reviews, see Randal, 2000; Thompson et al., 1999; Hamby and Showalter, 1999) . Included among the key tyrosine kinase targets that have generated the most interest in the scienti®c and patent (Connell, 2000) literature are PDGFR, VEGFR, FGFR and tie-2. The key development candidates targeting PDGFR, STI 571 and SU101, were described above, though neither compound is likely to reveal the clinical utility of PDGFR-directed inhibition of angiogenesis due to their multiple mechanisms of action. Agents that selectively target FGFR and tie-2 are not known to be in development, though several drugs targeting VEGFR have inhibitory activity vs FGFR. As such, the focus of the remainder of this overview will be on the clinical candidates targeting VEGFR. Two high anity receptors for VEGF have been identi®ed and characterized on human endothelial cells,¯t-1 and KDR. KDR appears to be expressed primarily on activated endothelial cells and is thought to be more of a key driver of mitogenic responses commonly found in neovascularizing tumors, while¯t-1 is expressed on multiple other cell types (Plate et al., 1994; Wedge et al., 2000a) . For the purposes of this review, the terms KDR and VEGFR will be used interchangeably, unless otherwise speci®ed.
SU 5416 and SU 6668
The former SUGEN organization (now part of Pharmacia) has clearly set the early pace in the race to identify and develop inhibitors of the VEGFR tyrosine kinase. Eorts towards this end have initially focused on the indolin-2-one pharmacophore (Figure 1) . Among the earliest compounds of this class was SU 5416, which was found to be a potent inhibitor of the kinase activities of both VEGFR and PDGFR. Inhibition of these two tyrosine kinases was found to be competitive with ATP, but the inhibition of FGFR, which occurred at SU 5416 concentrations some 100-fold higher, was found in kinetic experiments to be`mixed' competitive and non-competitive (Mendel et al., 2000) . It has been speculated that the latter result is due to speci®c biopharmaceutical properties of the compound, which is both lipophilic and potentially reactive in nature. Consistent with this concept are preliminary observations that the inhibition of VEGFdependent endothelial cell proliferation by SU 5416 has both a rapid onset and a pseudo-irreversible behavior which may be due to high intracellular levels of compound (Mendel et al., 2000) . Inhibition of endothelial cell proliferation translated to anti-tumor ecacy in a number of human xenograft and rodent tumor models (Fong et al., 1999) . In these studies, no data were generated to relate drug exposure (said to be very short-lived in rodents), or biochemical inhibition of VEGFR or PDGFR, to anti-tumor ecacy. Interestingly, the ecacy of SU 5416 was found to be greater in slower-growing vs faster growing solid tumor xenografts, which led Fong et al. (1999) to speculate that SU 5416 might bind preferentially to resting vs activated tyrosine kinases on endothelial cells. This would be at odds with other data suggesting that quinazolines bind more avidly to activated kinases (Levitzki and Bohmer, 1998) but, if true, may bode well for human ecacy in a majority of clinical settings.
Phase I studies were carried out in 69 advanced disease patients, with SU 5416 dosed i.v. twice weekly. Patients were treated at 13 dose levels between 4.4 ± 190 mg/m 2 /day; at the highest dose, a dose limiting toxicity (projectile vomiting) was observed . Induction of metabolism was noted in all patients, either due to the parent drug, a metabolite or dexamethasone premedication, and the elimination half-life was found to be 55 min . Early signs of ecacy were also apparent, with objective responses seen in three patients (Kaposi's sarcoma, metastatic basal cell and colorectal cancer); seven patients remained on study for more than 6 months, while two remained on study for greater than 18 months Mendel et al., 2000) . Given these results, SU 5416 has been advanced into multiple Phase II and III at an initial recommended dose of 145 mg/m 2 , which is sucient to produce systemic exposure comparable to what was required to yield eective tumor growth inhibition in animals . This dose is also within 30% of the human maximally tolerated dose (190 mg/m 2 ). The ongoing development plan includes large studies in NSCLC and colorectal cancer to assess the ecacy of SU 5416 both as a single agent and in combination with standard chemotherapies (Mendel et al., 2000) .
A related agent in development, SU 6668 (Figure 1 ), combines a less selective inhibitory pro®le (inhibition of FGFR in addition to PDGFR and VEGFR) with a more favorable biopharmaceutical pro®le . SU 6668 has a signi®cantly lower K i for PDGFR relative to VEGFR or FGFR (8 nM vs 2.1 and 1.2 mM, respectively), a result which appeared consistent with homology models of the respective active sites, but inconsistent with the cellular eects of SU 6668 (VEGFR-stimulated mitogenesis of endothelial cells much more potently inhibited relative to either PDGFR or FGFR) . Like SU 5416, SU 6668 was found to be potent and ecacious in a variety of tumor models. Unlike SU 5416, which was dosed i.p. in a DMSO-based vehicle, ecacy was achievable with SU 6668 when dosed orally each day in a cremaphore-based vehicle. In Phase I studies, SU 6668 was administered orally once daily to 16 patients with advanced malignancies, at dose levels between 100 ± 1600 mg/m 2 /day (Rosen et al., 2000) . Nine of 16 patients remained on study for up to 28 weeks while the remaining seven patients had progressive disease. Dose limiting toxicities were not observed, and dose escalation was said to be ongoing. Two patients at 1600 mg/m 2 developed liver function abnormalities, but both had potentially confounding liver disease. Other possible drug related toxicities included nausea, headache, fatigue and changes in bowel movements. Pharmacokinetic data suggested that SU 6668 had a moderate-high clearance (78 l/ day/m 2 ) and a somewhat improved elimination half-life of 2.5 h relative to SU 5416 (Rosen et al., 2000) . Phase II studies in multiple tumor types have apparently been initiated.
ZD4190 and ZD6474 ZD4190 is a quinazoline-based VEGFR inhibitor (Figure 1 ) said to have entered Phase I in early 2000. ZD6474 is thought to be from the same structural class, but AstraZeneca has not yet disclosed the speci®c structure. ZD4190 inhibits both KDR and¯t-1 (IC 50 values of 29 and 708 nM, respectively), and much less potent at inhibiting FGFR (approximately 200-fold relative to KDR). The compound is also 30-fold more potent at inhibiting VEGF-mediated endothelial cell growth relative to FGF-stimulated cell growth (IC 50 values of 50 and 1530 nM, respectively) (Wedge et al., 2000a) . In vivo, the compound was found to inhibit capillary invasion of cartilage (increased epiphyseal growth plate area), and to inhibit the growth of four human tumor xenografts in a dose-dependent manner with daily oral administration (Wedge et al., 2000a) . Direct measurements of tumor vascular endothelial permeability, using contrast medium-enhanced MRI indicated that acute ZD4190 treatment produced measurable changes in vascular permeability at doses which yielded antitumor activity during chronic administration (Wedge et al., 1999) . ZD6474, the second putative development candidate, is unique among small molecule angiogenesis inhibitors, in that it is found to induce signi®cant regressions in PC-3 tumors of varying size, with greatest eects being produced in the largest tumors (Wedge et al., 2000b ). An intermittent ZD6474 treatment schedule, involving withdrawal of compound for 4 weeks, revealed that tumor re-growth could be halted and marked regressions could again be induced in these tumors upon re-treatment. While the preclinical data for both compounds appear to be very promising, Phase I results for neither ZD4190 nor ZD6474 have yet been disclosed.
PTK 787
Novartis is reported to be developing PTK 787, which has an anilinophthalazine pharmacophore related to but distinct from the quinazolines described above (Figure 1) . The compound is a potent inhibitor of both major human VEGFR (IC 50 values of 37 and 77 nM for KDR and t-1, respectively) and, like STI 571, it provides potent (sub-micromolar) inhibition of PDGFR and c-kit but does not inhibit v-abl, EGFR or FGFR . PTK 787 inhibits VEGF-induced KDR autophosphorylation and mitogenesis, and promotes endothelial cell apoptosis, at a similar concentration . The compound also has good biopharmaceutical properties (plasma concentrations 41 mM 8 h after administration of a 50 mg/kg oral dose to mice), and impressive antiangiogenic (ED 50 512.5 mg/kg/day for inhibition of angiogenesis in a s.c. growth factor implant model) and anti-tumor activity (signi®cant growth inhibition in six dierent human tumor xenograft models at daily oral doses of 25 ± 75 mg/kg) . A key issue in the ®eld of anti-angiogenesis research has long been the fear that inhibition of tumor angiogenesis would also impair normal angiogenesis, such as that in wound healing. Given that most solid tumors are managed using multi-modality treatments that include surgery, this has been a theoretical limitation to inhibitors of angiogenesis. Interestingly, PTK 787 appears to have much less ecacy as an inhibitor of physiological angiogenesis of wound healing than as an eective blocker of tumor angiogenesis. Daily dosing of rats up to 50 mg/kg day did not impair the healing or decrease the tensile strength of full-thickness incisional wounds . Data on the antitumor activity of PTK 787 were recently extended to a renal tumor implant model, which was used to show that the compound could also inhibit both primary tumor growth and the emergence of tumor metastasis to the lung. Using a non-invasive (color Doppler imaging) surrogate endpoint, a commensurate decrease in renal artery blood¯ow could also be observed after chronic treatment . Thus, PTK 787 appears to show signi®cant preclinical ecacy, and to produce potent anti-tumor eects under well-tolerated dosing regimens. The preclinical toxicological pro®le and the human pharmacokinetics of this compound have not yet been disclosed. 
Development issues
It is clear that the development of newer agents like the tyrosine kinase inhibitors will require new concepts and clinical paradigms that are distinctly dierent from those used to develop the well-known cytotoxic agents commonly used in cancer chemotherapy. Some recent commentaries have done an outstanding job at framing these development issues (Sausville, 2000; Workman, 2000; Hudes, 1999; Eisenhauer, 1998) . Paramount among these is the need for nonconventional endpoints in clinical trial design, and for the identi®cation, validation and implementation of surrogate endpoints which may help direct dosemodulation during therapy. From the examples provided above, it is clear that for several agents (Iressa, 774; SU 5416) , the presumed ecacious dose in humans is very close to the maximally tolerated dose. None of these agents has yet been in a clinical trial designed to probe a broader aspect of ecacious dose range. Given the somewhat poor performance of preclinical ecacy models in predicting eective plasma concentrations in humans, organizations developing these new agents often resort to targeting some multiple of the plasma concentration required to generate ecacy in animal models, without ®rst gaining an understanding as to whether clinical ecacy is doseresponsive, or that most patients are not being dosed at a level well-along on the plateau of the dose-response curve. Non-invasive approaches (Doppler and contrast agent imaging for VEGFR inhibitors) and invasive approaches (tumor and tissue sampling pre-and posttreatment for EGFR inhibitors) are being developed to aid in the assessment of minimally and maximally eective doses during the ®rst days and weeks of clinical trial. The development of these surrogate endpoints is occurring on a parallel path with the agents themselves, probably too late to help de®ne the dose-response, the minimally-and maximally-eective dose, or the most ecient development paradigm.
A second key issue is one of the biochemical selectivity of tyrosine kinase inhibitors, and the impact that it may have on both the ecacy and the safety of the clinical candidate. The current experience with both non-selective tyrosine kinase inhibitors (STI 571 and SU 5416) and selective compounds (Iressa 2 and CP-358,774) suggest that ecacy can be generated with either class of inhibitor, with modest, comparable safety margins. There could be an opportunity to assess the relative merits of EGFR-selective vs. pan erbB inhibitors when comparing the results of the trials with Iressa 2 , CP-358,774 and CI-1033, but the irreversibility of the latter candidate is likely to confound the comparisons of relative therapeutic index. A related issue is one of pre-screening patients for the overexpression of the target at which the tyrosine kinase is directed. This may perhaps be a non-issue for VEGFR and PDGFR inhibitors, which target transiently, focally activated receptors on normal cells. However, it is clear that there may be dierent approaches in dealing with this issue during the development of EGFR inhibitors. AstraZeneca has apparently not incorporated prospective measurements of EGFR over-expression in tumors from patients with NSCLC as an inclusion criteria in their Phase III trials with Iressa 2 . As mentioned previously, one can surmise that the rationale for this strategy was based on both the high proportion of NSCLC tumors that over-express EGFR, and by preclinical data showing that overexpression is not predictive of a drug combination antitumor response.
P®zer and Oncogene Science have executed at least one Phase II study with CP-358,774 in head and neck cancer patients where EGFR expression levels were evaluated as an entry criterion (Siu et al., 2000) . The basis of this strategy could be said to reside in the Genentech development experience with Herceptin
2
, in which all patients entered into clinical trial, and subsequently all patients receiving the approved commercial product, are ®rst pre-screened to detect the level of over-expression of erbB2 in their breast tumors. It is interesting to note that retrospective analyses attempting to relate the level of erbB2 expression to clinical response in patients treated with Herceptin 2 (Dowsett et al., 2000) have been inconsistent and unconvincing. It is somewhat troubling to see that so straight-forward an assay (immunohistochemistry) applied on a post hoc basis to understand an agent with so singular a mechanism of action (Herceptin 2 ) has led to so little insight. One can perhaps begin to guage the obstacles that may lie ahead for the development of surrogate endpoints, which encompasses the application of novel technologies applied in a prospective way to drugs with complex mechanisms of action and pharmacological eects. This is the next frontier for the development of these new therapies for cancer. As such, the next 5 ± 6 years are likely to be as challenging, and as exhilarating, as have been the past 5 ± 6 years.
Abbreviations ATP, adenosine triphosphate; EGF/EGFR, epidermal growth factor/EGF receptor; PDGF/PDGFR, plateletderived growth factor/PDGF receptor; CML, chronic myelogenous leukemia.
